摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-t-butyloxycarbonyl-4-(2-methyl-phenyl)-3-piperazinone | 148927-99-5

中文名称
——
中文别名
——
英文名称
1-t-butyloxycarbonyl-4-(2-methyl-phenyl)-3-piperazinone
英文别名
1,1-dimethylethyl 4-(2-methylphenyl)-3-oxo-1-piperazinecarboxylate;tert-butyl 4-(2-methylphenyl)-3-oxopiperazine-1-carboxylate
1-t-butyloxycarbonyl-4-(2-methyl-phenyl)-3-piperazinone化学式
CAS
148927-99-5
化学式
C16H22N2O3
mdl
——
分子量
290.362
InChiKey
STHYIQVNJALRTN-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.3
  • 重原子数:
    21
  • 可旋转键数:
    3
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.5
  • 拓扑面积:
    49.8
  • 氢给体数:
    0
  • 氢受体数:
    3

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    参考文献:
    名称:
    [EN] 4-BENZ0YL-1-SUBSTITUTED-PIPERAZIN-2-0NE DERIVATIVES AS P2X7 MODULATORS
    [FR] DÉRIVÉS DE 4-BENZOYL-1-SUBSTITUÉ-PIPÉRAZIN-2-ONE COMME MODULATEURS DE P2X7
    摘要:
    该发明提供了一个具有以下式(I)的化合物或其药用盐,其中:A为C1-6烷基,C3-6环烷基,-CH2-R6,-CHMe-R7,-CMe2-R7或可选择地取代的芳基;其中,当A为可选择地取代的芳基时,所述芳基可选择地取代为1至3个取代基,这些取代基可以相同或不同,选自卤素,C1-6烷基,-CF3,C1-4烷氧基,C1氟烷氧基,氰基,NR8R9;和吡啶基,其中吡啶基可选择地被一个甲基取代;R1为氯,氟,-CF3,氰基或C1-6烷基;R2、R3和R5独立地为氢,氟,氯,-CF3,氰基或C1-6烷基,使得R2、R3和R5中至少有一个不是氢;R4为氢。这些化合物和盐被认为是P2X7受体拮抗剂。该发明还提供了该化合物或盐用于制备用于治疗疼痛、炎症、类风湿关节炎、骨关节炎或神经退行性疾病的药物的用途。
    公开号:
    WO2009053459A1
  • 作为产物:
    参考文献:
    名称:
    [EN] 4-BENZ0YL-1-SUBSTITUTED-PIPERAZIN-2-0NE DERIVATIVES AS P2X7 MODULATORS
    [FR] DÉRIVÉS DE 4-BENZOYL-1-SUBSTITUÉ-PIPÉRAZIN-2-ONE COMME MODULATEURS DE P2X7
    摘要:
    该发明提供了一个具有以下式(I)的化合物或其药用盐,其中:A为C1-6烷基,C3-6环烷基,-CH2-R6,-CHMe-R7,-CMe2-R7或可选择地取代的芳基;其中,当A为可选择地取代的芳基时,所述芳基可选择地取代为1至3个取代基,这些取代基可以相同或不同,选自卤素,C1-6烷基,-CF3,C1-4烷氧基,C1氟烷氧基,氰基,NR8R9;和吡啶基,其中吡啶基可选择地被一个甲基取代;R1为氯,氟,-CF3,氰基或C1-6烷基;R2、R3和R5独立地为氢,氟,氯,-CF3,氰基或C1-6烷基,使得R2、R3和R5中至少有一个不是氢;R4为氢。这些化合物和盐被认为是P2X7受体拮抗剂。该发明还提供了该化合物或盐用于制备用于治疗疼痛、炎症、类风湿关节炎、骨关节炎或神经退行性疾病的药物的用途。
    公开号:
    WO2009053459A1
点击查看最新优质反应信息

文献信息

  • Camphorcarbonyl
    申请人:Merck & Co., Inc.
    公开号:US05686454A1
    公开(公告)日:1997-11-11
    The invention is directed to a series of novel compounds of the formula ##STR1## where Y is carbonyl or sulfonyl; R.sup.7 and R.sup.8 are alkyl, or R.sup.7 and R.sup.8, together with the carbon to which they are attached, form a C.sub.3-6 carbocyclic ring; R.sup.9 and R.sup.10 are each independently selected from hydrogen, hydroxyl, oximido, methyl, carboxyl, carboxyalkyl, unsubstituted or substituted alkoxycarbonyl, alkylcarbonyloxyalkyl, cyanoalkyl, hydroxyalkyl or unsubstituted amino; R.sup.11 is hydrogen, oxo, --N(R.sup.12)--CO--R.sup.13 or --CO--N(R.sup.14)--R.sup.15 ; R.sup.12 is hydrogen or unsubstituted or substituted alkyl; R.sup.13 is alkoxyl, unsubstituted or substituted heterocyclic rings selected from ##STR2## or unsubstituted or substituted alkyl; and R.sup.14 and R.sup.15 are each independently selected from hydrogen or unsubstituted or substituted alkyl. The Y moiety cannot be bonded to the camphor ring at the 3 or 6 positions. Such compounds are oxytocin antagonists useful in the treatment of preterm labor, dysmenorrhea and for the stoppage of labor preparatory to cesarean delivery.
    该发明涉及一系列新颖化合物,其化学式为##STR1##其中Y为酰基或砜基;R.sup.7和R.sup.8为烷基,或者R.sup.7和R.sup.8与它们连接的碳原子一起形成一个C.sub.3-6螺环;R.sup.9和R.sup.10分别独立地选自氢、羟基、肟基、甲基、羧基、羧基烷基、未取代或取代的烷氧羰基、烷基羰氧基烷基、氰基烷基、羟基烷基或未取代氨基;R.sup.11为氢、氧、--N(R.sup.12)--CO--R.sup.13或--CO--N(R.sup.14)--R.sup.15;R.sup.12为氢或未取代或取代的烷基;R.sup.13为烷氧基、未取代或取代的杂环环选自##STR2##或未取代或取代的烷基;R.sup.14和R.sup.15分别独立地选自氢或未取代或取代的烷基。Y基不能与藿香环在3或6位置结合。这些化合物是催产素拮抗剂,用于治疗早产、痛经以及为剖宫产前停止分娩。
  • Piperazinylcamphorsulfonyl oxytocin antagonists
    申请人:Merck & Co., Inc.
    公开号:US05648352A1
    公开(公告)日:1997-07-15
    The invention is directed to a series of novel piperazinylcamphorsulfonyl compounds where the camphor ring is substituted by amides, amines, alkanes, alkenes, alkylamines, halogens, hydroxy, carboxy, alkoxycarbonyl and heterocyclic tings. Such compounds are oxytocin antagonists useful in the treatment of preterm labor, dysmenorrhea and for the stoppage of labor preparatory to cesarean delivery.
    本发明涉及一系列新型的哌嗪基樟脑磺酰化合物,其中樟脑环被酰胺、胺、烷基、烯烃、烷基胺、卤素、羟基、羧基、烷氧羰基和杂环取代。这些化合物是催产素拮抗剂,可用于治疗早产、痛经和剖腹产前停止分娩。
  • 4-BENZOYL-1-SUBSTITUTED-PIPERAZIN-2-ONE DERIVATIVES AS P2X7 MODULATORS
    申请人:Chambers Laura Jane
    公开号:US20100311749A1
    公开(公告)日:2010-12-09
    The invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein: A is C 1-6 alkyl, C 3-6 cycloalkyl, —CH 2 —R 6 , —CHMe-R 7 , —CMe 2 -R 7 , or optionally substituted aryl; wherein, when A is optionally substituted aryl, said aryl group is optionally substituted with 1 to 3 substituents, which may be the same or different, selected from the group consisting of halogen, C 1-6 alkyl, —CF 3 , C 1-4 alkoxy, C 1 fluoroalkoxy, cyano, NR 8 R 9 , and pyridyl wherein the pyridyl is optionally substituted by one methyl; R 1 is chlorine, fluorine, —CF 3 , cyano or C 1-6 alkyl; R 2 , R 3 and R 5 independently are hydrogen, fluorine, chlorine, —CF 3 , cyano or C 1-6 alkyl, such that at least one of R 2 , R 3 and R 5 is other than hydrogen; R 4 is hydrogen. These compounds and salts are thought to be P2X7 receptor antagonists. The invention also provides for the treatment of pain, inflammation, rheumatoid arthritis, osteoarthritis, or a neurodegenerative disease.
    本发明提供了式(I)的化合物或其药学上可接受的盐:其中:A是C1-6烷基,C3-6环烷基,-CH2-R6,-CHMe-R7,-CMe2-R7或可选地取代的芳基;其中,当A是可选地取代的芳基时,所述芳基基团可选地被1至3个取代基取代,所述取代基可以是相同的或不同的,选自卤素,C1-6烷基,-CF3,C1-4烷氧基,C1氟烷氧基,氰基,NR8R9和吡啶基,其中所述吡啶基可选择地被一个甲基取代;R1是氯,氟,-CF3,氰基或C1-6烷基;R2,R3和R5独立地是氢,氟,氯,-CF3,氰基或C1-6烷基,以至少其中一个R2,R3和R5不是氢;R4是氢。这些化合物和盐被认为是P2X7受体拮抗剂。本发明还提供了治疗疼痛,炎症,类风湿性关节炎,骨关节炎或神经退行性疾病的方法。
  • Piperazinyl(sulfon)amide derivatives of camphor as oxytocin antagonists
    申请人:MERCK & CO. INC.
    公开号:EP0532097A1
    公开(公告)日:1993-03-17
    Compounds of the formula: Compounds according to the structural formula, wherein R¹ is (1) hydrogen, (2) alkoxycarbonyl or (3) unsubstituted or substituted alkyl wherein said substituent is hydroxyl, alkoxyl, carboxyl, carboxyalkyl., alkylsulfonyl or alkoxycarbonyl; and R² is (1) hydrogen, (2) alkoxyl, (3) aralkoxyl, (4) alkoxycarbonyl, (5) alkoxycarbonylamino, (6) unsubstituted or substituted cycloalkyl, wherein said substituent is carboxyl, (7) unsubstituted or substituted phenyl wherein said substituent is one or more of carboxyl, carboxyalkyl or SO₃H, (8) unsubstituted or substituted amino, wherein said substituent is unsubstituted or substituted alkyl where said substituent is one or more of carboxyl, alkylsulfonyl or unsubstituted 5-membered heterocyclic rings having 1 or 2 heteroatoms, where said heteroatom is N, (9) unsubstituted or substituted rings of the formulae where said substituents are one or more of alkyl, carboxyl, carboxyalkyl, carboxyaralkyl, aralkylcarbonyl, aralkoxycarbonyl, alkoxycarbonyl, alkoxycarbonylalkyl, alkoxycarbonylaminoalkylcarbonyl, oxo or unsubstituted or substituted amino wherein said substituent is one or more of alkyl, carboxylalkyl, alkoxycarbonyl or alkoxycarbonylalkyl or (10) unsubstituted or substituted alkyl, wherein said substituent is one or more of hydroxyl, carboxyl, carboxyalkylphenyl, alkylsulfonyl, aminocarbonyl, alkylaminocarbonyl, aralkyl, aralkoxycarbonyl, halogen, alkoxycarbonyl, alkoxycarbonylalkyl, Het or unsubstituted or substituted amino, wherein said substituent is one or more of alkyl, alkylcarbonyl, alkylsulfonyl, carboxyalkyl, Cyc, alkoxycarbonyl, alkoxycarbonylalkyl, aralkoxycarbonyl, aminocarbonylalkyl, alkylaminocarbonyl, phenalkyl or unsubstituted or substituted alkylcarbonyl, where said substituent is a 5-membered heterocyclic ring having 1 or 2 heteroatoms and where said hetero atom is N, where Het is defined as for the above heterocyclic rings and where Cyc is defined as substituted or unsubstituted cycloalkyl wherein said substituent is selected from the group consisting of alkoxycarbonyl, carboxyl, hydroxyl, oxo or spiro-dioxolinyl . Such compounds are oxytocin antagonists useful in the treatment of preterm labor, dysmenorrhea and for the stoppage of labor preparatory to cesarean delivery.
    式中的化合物: 根据结构式的化合物,其中 R¹ 是 (1) 氢 (2) 烷氧基羰基或 (3) 未取代或取代的烷基,其中所述取代基为羟基、烷氧基、羧基、羧基烷基、烷基磺酰基或烷氧羰基;以及 R² 是 (1) 氢 (2) 烷氧基 (3) 芳烷氧基 (4) 烷氧羰基 (5) 烷氧羰基氨基 (6) 未取代或取代的环烷基,其中所述取代基为羧基、 (7) 未取代或取代的苯基,其中所述取代基为羧基、羧基烷基或 SO₃H 中的一个或多个、 (8) 未取代或取代的氨基,其中所述取代基为羧基、烷基磺酰基或具有 1 个或 2 个杂原子的未取代 5 元杂环中的一个或多个,其中所述杂原子为 N、 (9) 式中的未取代或取代环 其中所述取代基为烷基、羧基、羧基烷基、羧基烷基、烷基羰基、烷氧基羰基、烷氧基羰基、烷氧基羰基烷基、烷氧基羰基氨基烷基羰基、氧代或未取代或取代的氨基中的一个或多个,其中所述取代基为烷基、羧基烷基、烷氧基羰基或烷氧基羰基烷基中的一个或多个,或 (10) 未取代或取代的烷基,其中所述取代基为羟基、羧基、羧基烷基苯基、烷基磺酰基、氨基羰基、烷基氨基羰基、芳基、芳氧基羰基、卤素、烷氧基羰基中的一个或多个、烷氧基羰基、Het 或未取代或取代的氨基,其中所述取代基为烷基、烷基羰基、烷基磺酰基、羧基烷基、环烷基、烷氧基羰基、烷氧基羰基烷基、烷氧基羰基芳基、氨基羰基烷基中的一个或多个、烷基氨基羰基、苯基烷基或未取代或取代的烷基羰基,其中所述取代基为具有 1 个或 2 个杂原子的 5 元杂环,且所述杂原子为 N,Het 的定义与上述杂环相同,Cyc 的定义为取代或未取代的环烷基,其中所述取代基选自由烷氧基羰基、羧基、羟基、氧代或螺二氧环烷基组成的组。此类化合物是催产素拮抗剂,可用于治疗早产、痛经和剖腹产前的停产。
  • Substituted amine derivatives of piperazinylcamphorsulfonyl oxytocin antagonists
    申请人:MERCK & CO. INC.
    公开号:EP0533240A2
    公开(公告)日:1993-03-24
    Compounds of the formula: The compounds of formula I are oxytocin antagonists useful in the treatment of preterm labor, dysmenorrhea and for the stoppage of labor preparatory to cesarean delivery. Also disclosed are pharmaceutical compositions containing these compounds, methods of their use and methods of their preparation.
    式中的化合物: 式 I 的化合物是催产素拮抗剂,可用于治疗早产、痛经和剖宫产前的停产。还公开了含有这些化合物的药物组合物、其使用方法和制备方法。
查看更多